WO2020076141A1 - 재조합 rsv 생백신주 및 이의 제조 방법 - Google Patents
재조합 rsv 생백신주 및 이의 제조 방법 Download PDFInfo
- Publication number
- WO2020076141A1 WO2020076141A1 PCT/KR2019/013447 KR2019013447W WO2020076141A1 WO 2020076141 A1 WO2020076141 A1 WO 2020076141A1 KR 2019013447 W KR2019013447 W KR 2019013447W WO 2020076141 A1 WO2020076141 A1 WO 2020076141A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rsv
- virus
- protein
- recombinant
- gene
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18471—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18541—Use of virus, viral particle or viral elements as a vector
- C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Definitions
- the present invention relates to a live RSV vaccine and a method for producing the same, and more particularly to a live recombinant RSV vaccine and a method for producing the same.
- Respiratory Syncytial Virus is a virus that is prevalent worldwide and causes respiratory disease and is the leading cause of severe respiratory infection death in infants and young children. Infants and toddlers are the main targets, but it is known to cause respiratory diseases in patients with weakened immunity and respiratory diseases in the elderly. It is the second highest cause of respiratory disease following influenza, but the annual mortality rate from RSV per 100,000 people in infants under 1 year of age is about 1.3 to 2.5 times higher than influenza. According to a report from the WHO in 2002, 64 million people are infected with RSV each year, of which 160,000 die.
- inactivated vaccine For the purpose of defending RSV disease, a vaccine using an inactivated virus (inactivated vaccine) was developed at first, but it is inactivated due to the occurrence of serious side effects (ERD (enhanced respiratory disease)), such as the disease pathology being more severely induced.
- ERD enhanced respiratory disease
- the use of chemical vaccines has become impossible. Therefore, the researchers tried to develop a vaccine that does not have ERD induction and has an excellent ability to induce neutralizing antibodies.
- the live vaccine has the advantage of not inducing ERD and is capable of inducing neutralizing antibodies, but because RSV is very unstable, it is necessary to consider the stability and safety issues of the virus. When, there was a difficulty in developing the vaccine.
- RSV belongs to the subfamily Orthopneumoviridae belonging to the Mononegavirales order, Pneumoviridae family.
- RSV is a medium-sized virus of about 120-200nm. It has a surface structure composed of an envelope and three transmembrane proteins (F, G glycoproteins and SH protein), and a linear negative strand RNA composed of about 15,000 nucleotides is genome ( genome).
- RSV is divided into serotypes A and B by G protein.
- the RSV genome encodes 11 proteins, and is composed of parts encoding Structural and Non-structural proteins.
- Non-structural proteins are Nonstructural (NS) 1 and Nonstructural (NS) 2, and are antagonists of type I interferon, acting on mechanisms to avoid immune responses.
- fusion (F) protein, glyco (G) protein, and small hydrophobic (SH) protein are sugar proteins that form the surface of the virus, and nucleocapsid (N) protein, phosphoprotein (P), matrix (M) protein, and viral Polymerase (L), etc. constitutes the inside of a virus or plays an important role in virus replication.
- RSV F protein is an important component of the early entry of the virus entry and fusion with the cell membrane.
- the F protein antigen is a stabilized form of a pre-fusion type protein, and is difficult to produce and purify, and there is a problem that it is difficult to secure stability, and maintenance of efficacy is not easy.
- the inventors of the present invention seek to solve the instability of the F protein and develop a new safe form of RSV live vaccine.
- the present invention is intended to develop a live RSV vaccine strain having excellent stability by substituting or inserting a heterogeneous F protein with high stability.
- the present invention is intended to develop a live RSV vaccine strain having excellent safety (attenuated) by substitution or insertion with a heterogeneous F protein having high stability.
- the present invention seeks to develop a new recombinant RSV.
- the present invention is to provide a novel form of RSV vaccine capable of inducing a defense mechanism against RSV.
- the present invention is to provide a new type of vaccine that is capable of effective immune system operation by suppressing the immune escaping mechanism by not producing secreted G due to the G protein mutation of RSV.
- the present invention seeks to produce a bivalent vaccine by insertion or replacement of heterologous F proteins.
- One embodiment of the present invention provides a genetically recombined respiratory syncytial virus (RSV).
- RSV respiratory syncytial virus
- Genes encoding RSV envelope proteins are rearranged to provide a recombinant respiratory syncytial virus (RSV). That is, it provides a recombinant RSV virus in which an external gene is inserted into the RSV gene.
- an F protein derived from a virus other than RSV is inserted between a glycoprotein (G protein) of RSV and a gene encoding a fusion protein (F protein), or substituted for F protein of RSV.
- G protein glycoprotein
- F protein fusion protein
- a gene encoding an F protein derived from a heterologous virus of the Paramyxoviridae or Pneumoviridae family is inserted, or a gene encoding an F protein of RSV, or a gene encoding an F protein derived from a heterologous virus from the Paramyxoviridae or Pneumoviridae virus family It can be substituted with.
- the Paramyxoviridae may be any one or more selected from the group consisting of virus genus Aquaparamyxovirus, Avulavirus, Ferlavirus, Henipavirus, Morbillivirus, Respirovirus, Rubulavirus, Metapneumovirus, and Orthopneumovirus, preferably It may be any one or more selected from the group consisting of Measles virus, and Newcastle disease virus.
- the gene-recombinant respiratory syncytial virus is a gene encoding the envelope protein of the RSV A virus line as an RSV recombinant backbone having SEQ ID NO: 3 based on the human RSV A virus line of SEQ ID NO: 1 ( G protein and F protein expression domain) may be a rearranged recombinant RSV. Preferably it has a cDNA sequence of SEQ ID NO: 4-7. The sequence in which the restriction enzyme sequence was added to the anti-genome of RSV was shown in SEQ ID NO: 2.
- Another embodiment of the present invention provides a method of preparing an attenuated recombinant RSV comprising an expression vector comprising a polynucleotide encoding a recombinant RSV antigenomic.
- a first expression vector comprising a polynucleotide encoding a recombinant RSV antigenome;
- N, P, L, and a second expression vector comprising a polynucleotide encoding any one or more proteins selected from the group consisting of M2-1 proteins to produce recombinant RSV.
- the polynucleotide encoding the recombinant RSV antigenome includes a polynucleotide encoding all or part of a domain of a protein derived from a heterologous virus.
- the polynucleotide encoding the recombinant RSV antigenome included in the first expression vector may be any one selected from SEQ ID NOs: 4 to 7. Any one of the polynucleotides selected from SEQ ID NOs: 4 to 7 may be cDNA.
- the first expression vector may include a polynucleotide encoding the recombinant RSV antigenome in the pCC1 plasmid.
- the expression vector includes a gene that encodes a glycoprotein (G protein) and a fusion protein (F protein) of RSV, but F derived from a heterologous virus of the Paramyxoviridae or Pneumoviridae virus between the G protein and the gene encoding the F protein
- G protein glycoprotein
- F protein fusion protein
- a gene encoding a protein may be inserted, or a recombinant RSV gene substituted with a gene encoding an F protein derived from a paramyxoviridae or a heterologous virus from the family Pneumoviridae instead of a gene encoding RSV fusion protein (F protein) may be included.
- the recombinant RSV gene may be any one selected from SEQ ID NOs: 4 to 7.
- the recombinant RSV expression vector includes a T7 promoter, a hammerhead ribosome, a recombinant RSV gene, and a hepatitis delta virus ribosome; And T7 terminators in order.
- the Paramyxoviridae may be any one or more selected from the group consisting of virus genus Aquaparamyxovirus, Avulavirus, Ferlavirus, Henipavirus, Morbillivirus, Respirovirus, Rubulavirus, Metapneumovirus, and Orthopneumovirus, preferably It may be any one or more selected from the group consisting of Measles virus, and Newcastle disease virus.
- Another embodiment of the present invention provides an attenuated RSV live vaccine composition comprising a genetic recombinant respiratory syncytial virus (RSV) and a pharmaceutically acceptable carrier according to one embodiment of the present invention.
- RSV respiratory syncytial virus
- a pharmaceutically acceptable carrier according to one embodiment of the present invention.
- a method for preventing respiratory syncytial virus (RSV) infection by administering the live vaccine composition to the human body.
- the present invention provides a live RSV virus strain, and is a recombinant respiratory syncytial virus (RSV) in which a polynucleotide encoding all or part of a domain of F protein derived from a heterologous virus is inserted into the RSV genome, wherein the polynucleotide is i) It is inserted in place of the polynucleotide encoding some domains of the RSV F protein, or ii) into any part of the polynucleotides that make up the RSV gene.
- the recombinant RSV of the present invention can be used as an RSV vaccine strain, has excellent stability, and can be used as a vaccine because it is safe.
- the present invention is to provide a new type of RSV live vaccine in which a gene encoding the F protein of RSV is replaced with an F protein coding gene of a heterologous virus or an F protein coding gene of a heterologous virus is additionally introduced.
- Recombinant may refer to a case in which cells having different genetic traits coexist in one organism.
- “recombined” as used herein is different based on one genetic backbone. It means the case where a new genetic variation occurs because the genetic information (nucleic acid) of the individual is inserted.
- Recombinant RSV refers to an RSV or RSV-like virus that is directly or indirectly derived from a recombinant expression system, or is propagated from a virus or subviral particle produced therefrom.
- the recombinant expression system includes a recombinant expression vector, which comprises a functionally linked transcription unit, comprising at least one genetic element or combination of components that has regulatory functions in the expression of the RSV gene. Examples of elements are a promoter, a structure or coding sequence transcribed into RSV mRNA, an appropriate transcription initiation and termination sequence.
- genome is the total sequencing of an individual's gene, and refers to a collection of all genetic information in an organism.
- the genome of a virus is used to mean all the genetic information sequences of the whole virus.
- a “gene” may be understood as a portion encoding a protein, and may be DNA or RNA.
- introduction means that a new one is added from the original one, and mutation of a gene may be caused by introduction, and deletion, substitution, or insertion may occur.
- a new gene has been introduced into a genome may mean that a part of the entire gene sequence of an original individual may be substituted or inserted into a gene derived from a new individual. Due to this introduction, the genome sequence of the original individual (eg, backbone) may be longer, shorter, or longer.
- vaccine strain is also called a vaccine strain, and refers to a population of viruses isolated for use as a vaccine.
- Attenuated live vaccine is a vaccine made from attenuated respiratory syncytial virus (RSV), a toxic agent that is attenuated enough to not cause disease in the host, although the pathogen is still biologically active. It means a vaccine having.
- RSV respiratory syncytial virus
- anti-genome refers to a complementary (+) sense polynucleotide molecule that serves as a template for the synthesis of the progeny RSV genome.
- Natural RSV generally contains a (-) sense polynucleotide molecule, which codes for a viral protein, eg, glycoprotein (G), fusion (F), N, P, etc., via complementary viral mRNA.
- An attenuated RSV vaccine can be prepared by recombination of the cDNA encoding the RSV genome or antigenome.
- a gene encoding a protein or “a protein coding gene” means a gene that produces a protein.
- One embodiment of the present invention provides a live RSV vaccine strain having excellent stability and safety by inserting the F protein of a heterologous virus based on the RSV genome or substituting the F protein of the RSV and the F protein of the heterologous virus.
- One embodiment of the present invention provides a recombinant respiratory syncytial virus (RSV) vaccine strain in which a polynucleotide encoding a partial domain of an F protein derived from a heterologous virus is inserted into the RSV genome.
- RSV respiratory syncytial virus
- i) can be inserted in place of a polynucleotide encoding some domain of the RSV F protein, or ii) between a RSV F protein and a polynucleotide encoding the G protein domain.
- FIG. 2 is a diagram for showing a form in which polynucleotides encoding some domains of F protein of RSV are substituted with some domains of F protein derived from a foreign virus.
- FIG. 3 is a diagram for showing the form in which some domains of F proteins derived from a foreign virus are inserted while maintaining the polynucleotide encoding the F protein of RSV.
- the heterologous virus may be substituted with a gene encoding an F protein derived from a heterologous virus of the Paramyxoviridae or Pneumoviridae family.
- the Paramyxoviridae, or the Pneumoviridae family of viruses may be any one or more selected from the group consisting of virus genus Aquaparamyxovirus, Avulavirus, Ferlavirus, Henipavirus, Morbillivirus, Respirovirus, Rubulavirus, Metapneumovirus, and Orthopneumovirus, preferably It may be any one or more selected from the group consisting of Measles virus, and Newcastle disease virus.
- the measles virus and Newcastle disease virus can increase the stability of the virus and the safety of the live vaccine virus strain.
- the RSV virus genome underlying the present invention can use the wild type human RSV A virus strain of SEQ ID NO: 1.
- RSV virus strains such as RSV A strain, RSV B strain, HRSV A strain, HRSV B strain, BRSV strain, avian RSV strain, etc., but for the purposes of the present invention, RSV A virus strain may be preferred as the RSV basic backbone into which foreign genes are inserted. have. When a foreign gene is introduced using the RSV A virus strain, stability and safety of the recombinant virus produced are excellent, and a mutation rate may be small.
- One embodiment of the present invention is a first expression vector comprising a polynucleotide encoding a recombinant RSV antigenome containing a polynucleotide encoding a partial domain of a F protein derived from a heterologous virus, and
- a method of producing an attenuated RSV vaccine strain that produces recombinant RSV by expressing a second expression vector comprising a polynucleotide encoding any one or more proteins selected from the group consisting of N, P, L, and M2-1 proteins
- pCC1, pBR322, pUC, and pcDNA3.1 may be used, but when considering size or prevention of cytotoxicity during cloning, pCC1 may be preferably used for this purpose.
- the second expression vector may be a pCI neo vector, but is not limited thereto.
- RSV is a negative sense RNA virus.
- a separate helper gene required for gene synthesis is required.
- Recombined RSV antigenome and polynucleotides encoding respective N, P, L, and M2-1 proteins are introduced into cells by methods such as transfection, electroporation, mechanical insertion, and transduction can do.
- Virus infection may occur in cells such as Vero cell, Hep 2 cell, MRC 5 cell, etc., and production of the recombinant RSV virus strain of the present invention in Vero cell may be advantageous.
- RSV antigenomic RNA may be synthesized by extracellular transfection of cells expressing RSV protein.
- the polynucleotide encoding the recombinant RSV antigenome may be included in the first expression vector, the helper gene may be included in a vector different from the first expression vector (second expression vector), or may be included in the same vector.
- the polynucleotide encoding the recombinant RSV antigenome included in the first expression vector may include any polynucleotide selected from SEQ ID NOs: 4 to 7, and any one polynucleotide selected from SEQ ID NOs: 4 to 7 may be cDNA. You can.
- the first expression vector may include a polynucleotide encoding the recombinant RSV antigenome in the pCC1 plasmid, and for the purpose of facilitating the combination, induce mutation, modify the restriction enzyme site, or regulate the restriction enzyme site.
- the vector may be modified by inserting a synthesized polylinker containing.
- the pCC1 plasmid of the present invention can stabilize the recombinant RSV antigenome.
- the first expression vector comprising the recombinant RSV antigenomic comprises a T7 promoter, a hammerhead ribozyme, an RSV antigenomic, a hepatitis delta virus ribozyme, and a T7 terminator. It may be an expression vector containing the polynucleotide cDNA.
- the RSV antigenome includes F proteins of Measles virus, Newcastle disease virus, and parainfluenza virus (PIV), wherein the transmembrane (TM) and cytoplasmic tail of CT protein (CT) )
- TM transmembrane
- CT cytoplasmic tail of CT protein
- the polynucleotide encoding the domain may be derived from RSV, but may also be derived from the virus.
- One embodiment of the present invention provides an attenuated RSV vaccine strain prepared according to the above method.
- One embodiment of the invention RSV virus strain of the present application; And it provides a live RSV vaccine comprising a pharmaceutically acceptable carrier.
- Recombinant RSV vaccine strain produced by one embodiment of the present invention when used for vaccine use, the virus prepared according to the present invention can be used directly as a vaccine preparation, lyophilized, or mixed with a liquid. .
- the vaccine composition of the present invention includes any pharmaceutical substance that does not itself induce an immune response detrimental to the vertebrate receiving the composition, and any suitable diluent or excipient that can be administered without excessive toxicity with a recombinant RSV vaccine strain It includes a pharmaceutically acceptable carrier comprising a.
- pharmaceutically acceptable means listed in the United States Pharmacopoeia, European Pharmacopoeia, or vertebrate and other specifically recognized pharmacopoeia for use in humans.
- the RSV F antigen of the present invention is administered in an effective amount or amount (defined above) sufficient to stimulate an immune response against one or more strains of RSV virus.
- Such compositions can be used as vaccines and / or immunogenic compositions to induce protective immune responses in vertebrates.
- the concentration of the recombinant RSV antigen included in the vaccine is at least about 10 ⁇ g / mL, about 20 ⁇ g / mL, about 30 ⁇ g / mL, about 40 ⁇ g / mL, about 50 ⁇ g / mL, About 60 ⁇ g / mL, about 100 ⁇ g / mL, about 200 ⁇ g / mL, or about 500 ⁇ g / mL.
- the concentration of the immunogen is about 10 ⁇ g / mL to about 1 mg / mL, or about 20 ⁇ g / mL to about 500 ⁇ g / mL, or about 30 ⁇ g / mL to about 100 ⁇ g / mL or about 30 ⁇ g / mL To about 50 ⁇ g / mL.
- the concentration of the immunogen may be included from 10 ⁇ g / mL to 200 ⁇ g / mL.
- the vaccine or immunogen composition of the present invention can be administered to animals to induce an immune response against RSV.
- the animal is a human.
- the dosage can be adjusted within this range based on, for example, age, physical condition, weight, age, food, time of administration, and other clinical factors.
- the present invention includes a method of formulating a vaccine or immunogen composition that induces substantial immunity to a subject's infection or at least one symptom thereof, including adding an effective amount of an immunogen to the agent. Stimulation of substantial immunity by a single dose is preferred, but to achieve the desired effect, additional doses may be administered via the same or different routes. In newborns and infants, multiple administrations may be necessary, for example, to induce sufficient levels of immunity.
- a method of inducing substantial immunity against a viral infection or at least one symptom thereof in a subject comprises administering at least one effective amount of an RSV recombinant F protein or fragment or aggregate thereof.
- Methods for administering vaccines and / or immunogen agents include parenteral administration (e.g., endothelial, intramuscular, intravenous and subcutaneous), epidural and mucosal (e.g., nasal and oral or pulmonary routes or suppositories), It is not limited to this.
- the composition is administered intramuscularly, intravenously, subcutaneously, orally or intradermally.
- the composition is, for example, by injection or temporary injection, absorption through the epithelium or mucous membrane (e.g., oral mucosa, colon, conjunctiva, nasopharynx, central pharynx, vagina, urinary tract, bladder, intestinal mucosa, etc.) It can be administered by any convenient route and can be administered with other biologically active substances. Administration can be systemic or local.
- Prophylactic vaccine formulations are administered systemically by subcutaneous or intramuscular injection using needles and injections or by needle-free injection devices.
- the vaccine formulation is administered intranasally by droplet into the upper respiratory tract, large particle aerosol (greater than about 10 microns) or spray.
- the vaccine and / or immunogenic agent can be administered in a manner that targets mucosal tissue to elicit an immune response at the site of immunization.
- the site of administration is not limited.
- One embodiment of the present invention provides a method for preventing respiratory syncytial virus (RSV) infection by administering the RSV vaccine strain of the present invention to the human body.
- RSV respiratory syncytial virus
- the present invention provides a live RSV vaccine strain having excellent stability by substituting or inserting a heterogeneous F protein with high stability.
- a new recombinant RSV virus strain having an antibody production rate similar to that of wild-type RSV is provided while eliminating the instability and instability of the live vaccine.
- the present invention provides a live RSV vaccine strain having excellent safety (attenuated) by substitution or insertion with a heterogeneous F protein having high stability.
- the present invention provides a new type of RSV vaccine capable of inducing a defense mechanism against RSV.
- the present invention provides a new type of vaccine that does not produce secreted G due to the G protein mutation of RSV, and thus suppresses the immune escaping mechanism to enable effective immune system operation.
- the present invention can produce a bivalent vaccine by insertion or replacement of a heterologous F protein.
- the present invention provides a new recombinant RSV.
- 1 is a schematic diagram of RSV Genome.
- FIG. 2 is a schematic diagram showing the form of cutting the F protein site in the RSV genome (arrows indicate the cleavage site) and substituting the form of the F protein of a heterologous virus (eg, NDV).
- a heterologous virus eg, NDV
- Figure 3 is a schematic diagram showing the form of adding F protein of a heterologous virus (eg, MV) between G protein and F protein in the RSV genome.
- MV heterologous virus
- Figure 4 shows a picture of inserting F protein derived from an external virus by cutting the MluI and ApaI sites in the backbone of SEQ ID NO: 3.
- G GE represents the G protein gene end region
- F GS represents the F protein gene starting region
- F GE represents the F protein gene end region.
- the F protein of MV or NDV is inserted, but the T and C domains of F protein are those of RSV.
- Figure 5 shows the illustration of inserting F protein derived from an external virus by cutting the MluI and MluI sites in the backbone of SEQ ID NO: 3.
- the MluI and MluI cleavage sites are located between RS G protein and F protein.
- G GE represents the G protein gene end region
- F GS represents the F protein gene starting region
- F GE represents the F protein gene end region.
- the F protein of MV or NDVF is inserted, but the T and C domains of the added F protein are those of RSV.
- Figure 6 shows a schematic diagram of cloning the cDNA of the recombinant RSV virus of the present invention into a vector.
- FIG. 7 is a result showing attenuation through comparison of proliferation rate and proliferation titer for each cell (HEp2 cell, Vero cell, MRC5 cell) of recombinant RSV. Vaccine growth rate and titer were reduced compared to wild type RSV.
- FIG. 8 is a result showing the attenuation through the comparison of the growth rate and the growth titer in mice of recombinant RSV. Vaccine growth rate and titer were reduced compared to wild type RSV.
- Figure 10 shows the results of the mouse immune test of recombinant RSV, the results confirming the total antibody titer and neutralizing antibody titer. Sufficient antigen specific and neutralizing antibodies were induced in all groups except Mock. However, G7, a wild type virus fluorinated with formalin, showed relatively low total and neutralizing antibody prices.
- RSV backbone is wtRSVA_TH10654
- RSV backbone- MV F substitution is cRSVA_MVF_S,
- RSV backbone- NDV F substitution is cRSVA_NDVF_S,
- RSV backbone- MV F insertion is cRSVA_MVF_A
- RSV backbone- NDV F insertion was indicated by cRSVA_NDVF_A.
- the mock of FIG. 10 is shown as G1, WtRSVA as G2, cRSVA_MVF_S as G3, cRSVA_NDVF_S as G4, cRSVA_MVF_A as G5, cRSVA_NDVF_A as G6, and FIwtRSVA as G7.
- Figure 12 shows the results of the NDV immunogenicity test and neutralizing antibody
- the mocks of FIGS. 12 and 13 are G1, WtRSVA is G2, cRSVA_MVF_S is G3, cRSVA_NDVF_S is G4, cRSVA_MVF_A is G5, cRSVA_NDVF_A is G6, and FIwtRSVA is G7.
- a wild type RSV A virus strain having the following information was prepared as follows.
- Measles virus (MV) and Newcastle disease virus (NDV) were selected as F protein donor.
- the polynucleotide encoding the F protein of the RSV anti-genome was prepared by substituting or inserting the polynucleotide of the F protein derived from a heterologous virus.
- the genetic sequence is T7 promoter-hammerhead ribozyme-RSV anti-genome-hepatitis delta virus ribozyme-T7 terminator.
- T7 promoter sequence (TAATACGACTCACTATAGG) was inserted at the 5 ⁇ end.
- the hammerhead ribozyme sequence (T TTTTTCGCGT CTGATGAGGC CGTTAGGCCG AAACTCCTCT CCGGAGTC) was inserted following the T7 promotor sequence.
- the hammerhead ribozyme sequence was followed by a wild-type RSV anti-genome sequence and the following mutations were applied.
- GCGCGCC is inserted between 77nt and 78nt to generate AscI restriction enzyme sequence.
- AscI restriction enzyme sequence is GGCGCGCC ⁇ 8 bp>, but since the sequence of 77nt is G, only GCGCGCC ⁇ 7 bp> was inserted.
- Hepatitis delta virus ribozyme sequence followed by T7 terminator sequence (TAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG) is inserted.
- the designed gene (SEQ ID NO: 3) was cloned into a pCC1 vector after in vitro synthesis.
- the F protein gene sequence was removed and the corresponding measles virus F gene sequence was inserted.
- the anti-genome information of the Measles virus Edmonston strain (Moraten vaccine) (Accession No .; AF266287.1) was used.
- the F protein gene corresponds to 5449 to 7110 sequences, and 5449 to 6939 sequences except for the transmembrane region and cytoplasmic tail region sequences were used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the UTR sequence of the F protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the backbone construct A was cut with MluI and ApaI restriction enzymes, and the designed measles virus F gene was inserted.
- the F protein gene sequence was removed and the corresponding Newcastle disease virus F gene sequence was inserted.
- the anti-genome information of Newcastle disease virus I-2 strain (Accession No .; AY935499) was used.
- the F protein gene corresponds to 4544 to 6205 sequences, and 4544 to 6043 sequences except for the transmembrane region and cytoplasmic tail region sequences were used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the UTR sequence of the F protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- Backbone construct A was cut with MluI and ApaI restriction enzymes, and the designed Newcastle disease virus F gene was inserted.
- the constructs B and C recognize the restriction enzymes MluI / ApaI, insert amplified with Primer 1-Primer 2, and Primer 1 (forward) is 5 'ATAT ACGCGT gtattgttgcaaaagccatg, Primer 2 (reverse) Is 5 'ATAT GGGCCC tgttttatataactataaaatagaa.
- the measles virus F gene sequence was inserted between the G protein and F protein genes.
- the F protein gene corresponds to 5449 to 7110 sequences, and 5449 to 6939 sequences except for the transmembrane region and cytoplasmic tail region sequences were used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the 5 ⁇ UTR the 5 ⁇ UTR sequence of the F protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- 3 ⁇ UTR the 3 ⁇ UTR sequence of the G protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the backbone construct A is cut with MluI restriction enzyme and the designed measles virus F gene is inserted.
- Newcastle disease virus F gene sequence was inserted between the G protein and the F protein gene.
- the F protein gene corresponds to 4544 to 6205 sequences, and 4544 to 6043 sequences except for the transmembrane region and cytoplasmic tail region sequences were used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the sequence of wild-type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the 5 ⁇ UTR the 5 ⁇ UTR sequence of the F protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- 3 ⁇ UTR the 3 ⁇ UTR sequence of the G protein gene of wild type human respiratory syncytial virus strain RSVA / TH_10654 was used.
- the Backbone construct A was cut with MluI restriction enzyme and the designed Newcastle disease virus F gene was inserted.
- a heterologous viral gene is inserted into a site recognized by the restriction enzyme MluI, and insert amplification is performed with Primer 1-Primer 3.
- Primer 1 forward
- Primer 3 reverse
- RSV is a negative sense RNA virus that uses reverse genetics to insert helper genes (N, P, L, and M2-1 protein coding genes of RSV) necessary for gene synthesis when producing viruses in vitro.
- the N protein gene is cloned using the restriction enzymes XhoI and MluI into the pCI neo vector, sequences 1119 to 2294 of the wild-type human respiratory syncytial virus strain RSVA / TH_10654 anti-genome.
- the P protein gene is cloned from the wild type human respiratory syncytial virus strain RSVA / TH_10654 anti-genome from 2326 to 3051 sequences using restriction enzymes XhoI and MluI in pCI neo vector.
- the M2-1 protein gene is cloned into the pCI neo vector using the restriction enzymes XhoI and MluI with the sequences 7647 to 8231 of the wild-type human respiratory syncytial virus strain RSVA / TH_10654 anti-genome.
- the N protein gene is shown in SEQ ID NO: 8, the P protein gene in SEQ ID NO: 9, the M2-1 protein gene in SEQ ID NO: 10, and the L protein gene in SEQ ID NO: 11.
- BHK cells were prepared in a 6-well plate at a concentration of 4 x 10 5 cells / well.
- T7 polymerase expression vector 2 ug of T7 polymerase expression vector, 2 ug of RSV full length anti-genome vector, 4 kinds of helper gene vector (N, P, M2-1, L) 6 plasmids of 1 ug each were mixed with 10 ul of lipofectamine3000 at the same time and 10 After reacting for a minute, it was transfected into BHK cells. Drop the droplets so that they can be uniformly applied to the cells and shake them 2-3 times to mix well.
- helper gene vector N, P, M2-1, L
- viruses Five viruses were infected with 0.1 MOI in Vero cell, HEp2 cell, and MRC-5 and cultured for 9 days. Virus cultures were collected every 1 day and virus titer was analyzed using q-PCR.
- the vaccine strain which is a mutant virus, was attenuated by decreasing the growth rate and the growth titer compared to the wild-type virus. It can be seen that the recombined viruses can be used as live vaccines. DPI means days post infection.
- viruses Five viruses were administered by concentration of 10 1 to 10 7 pfu / mouse through IN route of BALB / c mice. It was confirmed that viremia was attenuated by detecting q-PCR in blood on day 1-7.
- FIG. 8 As can be seen in Figure 8, it can be seen that the attenuated in vivo after inoculation compared to the wild-type RSV A virus, through which it was confirmed that the recombinant RSV can be used as a new virus strain.
- Mock, wtRSVA, cRSVA_MVF_S, cRSVA_NDVF_S, cRSVA_MVF_A, and cRSVA_NDVF_A were immunized twice in mouse IM at a concentration of 1x10 5 pfu / mouse. After 2 weeks, the serum of each mouse was separated, and the total antibody value was measured by ELISA and the neutralizing antibody was measured by plaque reduction neutralization test. The results are shown in FIG. 10. It was confirmed that in all groups except Mock, antibodies specific for RSV antigen and neutralizing virus infection were sufficiently formed.
- Mock is G1
- WtRSVA is G2
- cRSVA_MVF_S is G3
- cRSVA_NDVF_S is G4
- cRSVA_MVF_A is G5
- cRSVA_NDVF_A is G6, and FIwtRSVA is G7.
- mice Five viruses were inoculated twice into the IM of mice at a concentration of 10 5 pfu / mouse every two weeks. Two weeks after immunization, wild-type RSV was challenged to the mouse nasal cavity at a concentration of 2x10 6 pfu / mouse. On day 1-12, viremia was detected in blood through q-PCR, and body weight change was measured. The results are shown in FIG. 11. It was found that all immune groups effectively inhibited viral infection. In particular, it was found that the infection was suppressed at a level similar to that of the wild-type virus strain, and that the degree of viral infection in blood was significantly less than that of the inactivated strain.
- the total antibody value and neutralizing antibody value for NDV and MV antigens were measured using the same serum.
- ELISA was performed by coating the MV and DNV antigens, respectively, to measure the total antibody value.
- concentrations that inhibited infection of MV and NDV, respectively were measured by plaque inhibition assay.
- antibodies and virus-neutralizing antibodies specific to each antigen were sufficiently formed only in the group having F antigens of MV and NDV, as shown in FIGS. 12 and 13.
- antibodies were not formed in each antigen, and neutralizing antibodies were not induced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (16)
- RSV의 외피 단백질을 코딩하는 유전자가 재배열된 유전자 재조합 호흡기 세포융합 바이러스(RSV)로,RSV의 당단백질(G 단백질)과 융합 단백질 (F 단백질)을 코딩하는 유전자 사이에 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스 유래의 F 단백질을 코딩하는 유전자가 삽입되거나,RSV의 F 단백질을 코딩하는 유전자가 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스 유래의 F 단백질을 코딩하는 유전자로 치환된 유전자 재조합 호흡기 세포융합 바이러스(RSV).
- 제1항에 있어서, 상기 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스는 Aquaparamyxovirus, Avulavirus, Ferlavirus, Henipavirus , Morbillivirus, Respirovirus , Rubulavirus, Metapneumovirus, 및 Orthopneumovirus로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 유전자 재조합 호흡기 세포융합 바이러스(RSV).
- 제1항에 있어서, 상기 이종 바이러스는 홍역 바이러스(Measles virus), 및 뉴캐슬병 바이러스(Newcastle disease virus)로 이루어진 군에서 선택된 어느 하나 이상인, 유전자 재조합 호흡기 세포융합 바이러스(RSV).
- 제1항에 있어서, 상기 유전자 재조합 호흡기 세포융합 바이러스(RSV)는 서열번호 1의 야생형 인간 RSV A 바이러스주의 외피 단백질을 코딩하는 유전자가 재배열된, 재조합 RSV.
- 재조합 RSV 안티게놈을 코딩하는 폴리뉴클레오티드를 포함하는 제1 발현 벡터; 및N, P, L, 및 M2-1 단백질로 이루어진 군에서 선택된 어느 하나 이상의 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 제2 발현 벡터를 함께 발현시켜 재조합 RSV를 생산하며,상기 재조합 RSV 안티게놈을 코딩하는 폴리뉴클레오티드는 이종의 바이러스로부터 유래된 단백질의 전체 또는 일부 도메인을 암호화하는 폴리뉴클레오티드가 포함된, 약독화된 재조합 RSV를 제조하는 방법.
- 제5항에 있어서, 상기 제1 발현 벡터에 포함되는 재조합 RSV 안티게놈을 코딩하는 폴리뉴클레오티드는 서열번호 4 내지 7 중에서 선택된 어느 하나인, 방법.
- 제6항에 있어서, 상기 서열번호 4 내지 7 중에서 선택된 어느 하나의 폴리뉴클레오티드는 cDNA인, 방법.
- 제5항에 있어서, 상기 제1 발현 벡터는 pCC1 플라스미드에 상기 재조합 RSV 안티게놈을 코딩하는 폴리뉴클레오티드가 포함된, 방법.
- 제5항에 있어서, 상기 재조합 RSV 안티게놈을 코딩하는 폴리뉴클레오티드는 이종의 바이러스로부터 유래된 단백질은 F 단백질인 것을 특징으로 하는, 방법.
- 재조합 RSV 발현벡터로,RSV의 당단백질(G 단백질)과 융합 단백질 (F 단백질)을 코딩하는 유전자를 포함하되, 상기 G 단백질과 F 단백질을 코딩하는 유전자 사이에 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스 유래의 F 단백질을 코딩하는 유전자가 삽입되거나,RSV의 융합 단백질 (F 단백질)을 코딩하는 유전자 대신 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스 유래의 F 단백질을 코딩하는 유전자로 치환된 재조합 RSV 유전자가 포함된, 재조합 RSV 발현용 벡터
- 제10항에 있어서, 상기 재조합 RSV 유전자는 서열번호 4 내지 7 중에서 선택된 어느 하나인 재조합 RSV 발현용 벡터.
- 제10항에 있어서, 상기 재조합 RSV 발현용 벡터는 T7 프로모터, 해머헤드 라이보좀, 재조합 RSV 유전자, 헤파티티스 델타 바이러스 라이보좀; 및 T7 종결자를 순서대로 포함하는 것을 특징으로 하는 재조합 RSV 발현용 벡터.
- 제10항에 있어서, 상기 Paramyxoviridae, 또는 Pneumoviridae 바이러스과의 이종 바이러스는 홍역 바이러스(Measles virus), 및 뉴캐슬병 바이러스(Newcastle disease virus)로 이루어진 군에서 선택된 어느 하나 이상인 재조합 RSV 발현용 벡터.
- 제1항 내지 제4항 중 어느 하나의 항에 따른 유전자 재조합 호흡기 세포융합 바이러스(RSV) 및약학적으로 허용 가능한 담체를 포함하는 약독화된 RSV 생백신 조성물.
- 제1항 내지 제4항 중 어느 하나의 항에 따른 유전자 재조합 호흡기 세포융합 바이러스(RSV) 및약학적으로 허용 가능한 담체를 포함하는, RSV; 및 홍역 바이러스(Measles virus (MV)) 또는 뉴캐슬병 바이러스(Newcastle disease virus(NDV)) 감염 예방용 2가 백신 조성물.
- 제14항의 RSV 백신 조성물을 인체에 투여하여 호흡기 세포융합 바이러스(RSV) 감염을 예방하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021006970-4A BR112021006970A2 (pt) | 2018-10-12 | 2019-10-14 | cepa de vacina viva de rsv recombinante e método para produzir a mesma |
CA3115979A CA3115979A1 (en) | 2018-10-12 | 2019-10-14 | Recombinant rsv live vaccine strain and production method therefor |
CN201980073535.2A CN112969786A (zh) | 2018-10-12 | 2019-10-14 | 重组呼吸道合胞病毒活疫苗株及其制备方法 |
US17/283,658 US20210355169A1 (en) | 2018-10-12 | 2019-10-14 | Recombinant rsv live vaccine strain and production method therefor |
EP19870535.2A EP3868874A1 (en) | 2018-10-12 | 2019-10-14 | Recombinant rsv live vaccine strain and production method therefor |
JP2021520144A JP2022504777A (ja) | 2018-10-12 | 2019-10-14 | 組換えrsv生ワクチン株及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180122162 | 2018-10-12 | ||
KR10-2018-0122162 | 2018-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020076141A1 true WO2020076141A1 (ko) | 2020-04-16 |
Family
ID=70164206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/013447 WO2020076141A1 (ko) | 2018-10-12 | 2019-10-14 | 재조합 rsv 생백신주 및 이의 제조 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210355169A1 (ko) |
EP (1) | EP3868874A1 (ko) |
JP (1) | JP2022504777A (ko) |
KR (1) | KR102567994B1 (ko) |
CN (1) | CN112969786A (ko) |
BR (1) | BR112021006970A2 (ko) |
CA (1) | CA3115979A1 (ko) |
WO (1) | WO2020076141A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023166079A1 (en) | 2022-03-02 | 2023-09-07 | Vaxxel | Vaccine composition against two respiratory viruses |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020092343A (ko) * | 1999-07-09 | 2002-12-11 | 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 | 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법 |
KR20140077169A (ko) * | 2011-09-30 | 2014-06-23 | 노바백스, 인코포레이티드 | 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 rsv f 백신 |
JP2016202113A (ja) * | 2015-04-27 | 2016-12-08 | 学校法人北里研究所 | 組換え麻疹ウイルス |
JP2018503402A (ja) * | 2015-01-20 | 2018-02-08 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用 |
KR20180122162A (ko) | 2017-05-02 | 2018-11-12 | 이순동 | 다용도 물품 정리대 |
-
2019
- 2019-10-14 WO PCT/KR2019/013447 patent/WO2020076141A1/ko active Application Filing
- 2019-10-14 CA CA3115979A patent/CA3115979A1/en active Pending
- 2019-10-14 KR KR1020190127265A patent/KR102567994B1/ko active IP Right Grant
- 2019-10-14 CN CN201980073535.2A patent/CN112969786A/zh active Pending
- 2019-10-14 JP JP2021520144A patent/JP2022504777A/ja active Pending
- 2019-10-14 EP EP19870535.2A patent/EP3868874A1/en not_active Withdrawn
- 2019-10-14 US US17/283,658 patent/US20210355169A1/en active Pending
- 2019-10-14 BR BR112021006970-4A patent/BR112021006970A2/pt not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020092343A (ko) * | 1999-07-09 | 2002-12-11 | 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 | 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법 |
KR20140077169A (ko) * | 2011-09-30 | 2014-06-23 | 노바백스, 인코포레이티드 | 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 rsv f 백신 |
JP2018503402A (ja) * | 2015-01-20 | 2018-02-08 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用 |
JP2016202113A (ja) * | 2015-04-27 | 2016-12-08 | 学校法人北里研究所 | 組換え麻疹ウイルス |
KR20180122162A (ko) | 2017-05-02 | 2018-11-12 | 이순동 | 다용도 물품 정리대 |
Non-Patent Citations (3)
Title |
---|
"BAC-Based Recovery of Recombinant Respiratory Syncytial Virus (RSV", REVERSE GENETICS OF RNA VIRUSES, pages 111 - 124 |
"RNA Virus Reverse Genetics and Vaccine Design", VIRUSES, vol. 6, 2014, pages 2531 - 2550 |
ROSTAD, C. A. ET AL.: "A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats", J. VIROL., vol. 90, no. 16, 2016, pages 7508 - 7518, XP055582324 * |
Also Published As
Publication number | Publication date |
---|---|
KR102567994B1 (ko) | 2023-08-17 |
BR112021006970A2 (pt) | 2021-07-27 |
KR20200041821A (ko) | 2020-04-22 |
CN112969786A (zh) | 2021-06-15 |
JP2022504777A (ja) | 2022-01-13 |
EP3868874A1 (en) | 2021-08-25 |
CA3115979A1 (en) | 2020-04-16 |
US20210355169A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU684252B2 (en) | Vaccines against Aujeszky's disease and other animal diseases containing pseudorabies virus mutants | |
US20220325252A1 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
US20210330782A1 (en) | Genetically stable live attenuated respiratory syncytial virus vaccine and its production | |
WO2020076141A1 (ko) | 재조합 rsv 생백신주 및 이의 제조 방법 | |
US9034343B2 (en) | Attenuated human parainfluenza virus, methods and uses thereof | |
WO2019212312A1 (ko) | 키메라 지카바이러스 백신 | |
US20220324917A1 (en) | Recombinant rsv live vaccine strain and the preparing method thereof | |
US20070003577A1 (en) | Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections | |
JP2022523157A (ja) | キメラ型RSVおよびhMPV Fタンパク質、免疫原性組成物、ならびに使用方法 | |
WO2022163902A1 (ko) | 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물 | |
WO2023055154A1 (ko) | 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법 | |
WO2022092921A1 (ko) | 사스-코로나바이러스-2 항원을 포함하는 바이럴 벡터 및 이의 이용 | |
WO2023003332A1 (ko) | 식물 기반 covid-19 변이 재조합 스파이크 단백질 발현 벡터 및 상기 발현 벡터를 이용한 재조합 단백질 | |
WO2023027562A1 (ko) | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 | |
US20100330120A1 (en) | Human parainfluenza viruses having separated p and c genes | |
WO2023244044A1 (ko) | 변형된 코로나바이러스 스파이크 항원 단백질 및 이의 용도 | |
WO2022203404A1 (ko) | 뉴캐슬병 바이러스 벡터를 이용한 고역가 조류메타뉴모바이러스 백신 | |
WO2023204559A1 (ko) | 고역가 일본뇌염 바이러스 유전형 5형 및 이의 용도 | |
WO2022203117A1 (ko) | 뉴캐슬병 바이러스 벡터 기반 pten 유전자 삽입 재조합 뉴캐슬병 바이러스를 이용한 뇌종양 치료용 암용해바이러스 및 이를 이용한 뇌종양 치료용 조성물 | |
WO2022065889A1 (ko) | 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
RU2773746C2 (ru) | Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов | |
WO2023085760A1 (ko) | 신규한 재조합 뉴캣슬바이러스벡터 및 이를 포함하는 백신 조성물 | |
WO2022216025A1 (ko) | Sars-cov-2 항원을 발현하는 재조합 마이코박테리움 균주 및 이를 포함하는 백신 조성물 | |
WO2021153873A1 (ko) | 돼지유행성설사병바이러스 약독화 생백신주, 이를 포함하는 조성물, 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19870535 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3115979 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021520144 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021006970 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021111003 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019870535 Country of ref document: EP Effective date: 20210512 |
|
ENP | Entry into the national phase |
Ref document number: 112021006970 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210412 |